α-Adrenergic receptor function, arousal and sleep: Mechanisms and therapeutic implications

Pharmacopsychiatry

Volumn 45, Issue 6, 2012, Pages 209-216

  Broese, M ^a   Riemann, D ^a   Hein, L ^a   Nissen, C ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

receptors; arousal; clonidine; norepinephrine; prazosin; sleep

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; AMPHETAMINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BENZODIAZEPINE; CAFFEINE; CLONIDINE; DEXMEDETOMIDINE; GUANFACINE; MELATONIN; MIRTAZAPINE; MODAFINIL; PLACEBO; PRAZOSIN; TIZANIDINE; TRICYCLIC ANTIDEPRESSANT AGENT;

AROUSAL; ATTENTION DEFICIT DISORDER; BORDERLINE STATE; BRADYCARDIA; DIZZINESS; FATIGUE; HEART RATE; HUMAN; HYPOTENSION; LETHARGY; MENTAL DISEASE; MOLECULAR MECHANICS; NEUROTRANSMISSION; NONHUMAN; NORADRENERGIC SYSTEM; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; RESTLESS LEGS SYNDROME; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP; SLEEP DISORDER; SLEEP WAKING CYCLE; SOMNOLENCE; SPASTICITY; XEROSTOMIA;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; AROUSAL; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BORDERLINE PERSONALITY DISORDER; HUMANS; MODELS, NEUROLOGICAL; RECEPTORS, ADRENERGIC, ALPHA; SLEEP; SLEEP DISORDERS; STRESS DISORDERS, POST-TRAUMATIC;

EID: 84866419164     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0031-1299728     Document Type: Review

References (128)

1. Saper C B, Scammell T E, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature: 2005; 437 1257 1263
2. Berridge C W. Noradrenergic modulation of arousal. Brain Res Rev: 2008; 58 1 17
3. Borbely A A, Achermann P. Sleep homeostasis and models of sleep regulation. J Biol Rhythms: 1999; 14 557 568
4. Saper C B, Cano G, Scammell T E. Homeostatic, circadian, and emotional regulation of sleep. J Comp Neurol: 2005; 493 92 98
5. Dijk D J, Czeisler C A. Contribution of the circadian pacemaker and the sleep homeostat to sleep propensity, sleep structure, electroencephalographic slow waves, and sleep spindle activity in humans. J Neurosci: 1995; 15 3526 3538
6. Bjorness T E, Greene R W, Kelly C L et al. Adenosine and sleep control and function of the homeostatic sleep response by adenosine A1 receptors. Curr Neuropharmacol: 2009; 7 238 245
7. Nelson L E, Guo T Z, Lu J et al. The sedative component of anesthesia is mediated by GABA(A) receptors in an endogenous sleep pathway. Nat Neurosci: 2002; 5 979 984
8. Espana R A, Scammell T E. Sleep neurobiology from a clinical perspective. Sleep: 2011; 34 845 858
9. Sehgal A, Mignot E. Genetics of sleep and sleep disorders. Cell: 2011; 146 194 207
10. McCarley R W, Hobson J A. Neuronal excitability modulation over the sleep cycle: a structural and mathematical model. Science: 1975; 189 58 60
11. Berridge C W, Abercrombie E D. Relationship between locus coeruleus discharge rates and rates of norepinephrine release within neocortex as assessed by in vivo microdialysis. Neuroscience: 1999; 93 1263 1270
12. Berridge C W, Page M E, Valentino R J et al. Effects of locus coeruleus inactivation on electroencephalographic activity in neocortex and hippocampus. Neuroscience: 1993; 55 381 393
13. Foote S L, Bloom F E, Aston-Jones G. Nucleus locus ceruleus: new evidence of anatomical and physiological specificity. Physiol Rev: 1983; 63 844 914
14. Espana R A, Berridge C W. Organization of noradrenergic efferents to arousal-related basal forebrain structures. J Comp Neurol: 2006; 496 668 683
15. Aston-Jones G, Bloom F E. Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J Neurosci: 1981; 1 876 886
16. Shinba T, Shinozaki T, Mugishima G. Clonidine immediately after immobilization stress prevents long-lasting locomotion reduction in the rat. Prog Neuropsychopharmacol Biol Psychiatry: 2001; 25 1629 1640
17. Tanaka M, Kohno Y, Tsuda A et al. Differential effects of morphine on noradrenaline release in brain regions of stressed and non-stressed rats. Brain Res: 1983; 275 105 115
18. Foote S L, Aston-Jones G, Bloom F E. Impulse activity of locus coeruleus neurons in awake rats and monkeys is a function of sensory stimulation and arousal. Proc Natl Acad Sci USA: 1980; 77 3033 3037
19. Aston-Jones G, Cohen J D. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci: 2005; 28 403 450
20. Berridge C W, Isaac S O, Espana R A. Additive wake-promoting actions of medial basal forebrain noradrenergic alpha1- and beta-receptor stimulation. Behav Neurosci: 2003; 117 350 359
21. McCormick D A, Pape H C, Williamson A. Actions of norepinephrine in the cerebral cortex and thalamus: implications for function of the central noradrenergic system. Prog Brain Res: 1991; 88 293 305
22. Jodo E, Chiang C, Aston-Jones G. Potent excitatory influence of prefrontal cortex activity on noradrenergic locus coeruleus neurons. Neuroscience: 1998; 83 63 79
23. Bylund D B, Eikenberg D C, Hieble J P et al. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev: 1994; 46 121 136
24. Gilsbach R, Hein L. Presynaptic metabotropic receptors for acetylcholine and adrenaline/noradrenaline. Handb Exp Pharmacol: 2008; 261 288
25. Gilsbach R, Albarran-Juarez J, Hein L. Pre- versus postsynaptic signaling by alpha(2)-adrenoceptors. Curr Top Membr: 2011; 67 139 160
26. Matsuo S, Jang I S, Nabekura J et al. alpha 2-Adrenoceptor-mediated presynaptic modulation of GABAergic transmission in mechanically dissociated rat ventrolateral preoptic neurons. J Neurophysiol: 2003; 89 1640 1648
27. Liu Y W, Li J, Ye J H. Histamine regulates activities of neurons in the ventrolateral preoptic nucleus. J Physiol: 2010; 588 4103 4116
28. Mitchell H A, Weinshenker D. Good night and good luck: norepinephrine in sleep pharmacology. Biochem Pharmacol: 2010; 79 801 809
29. Kumar R. Approved and investigational uses of modafinil: an evidence-based review. Drugs: 2008; 68 1803 1839
30. Young J W, Geyer M A. Action of modafinil - increased motivation via the dopamine transporter inhibition and D1 receptors? Biol Psychiatry: 2010; 67 784 787
31. Godfrey J. Safety of therapeutic methylphenidate in adults: a systematic review of the evidence. J Psychopharmacol: 2009; 23 194 205
32. Leonard B E, McCartan D, White J et al. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol: 2004; 19 151 180
33. Sullivan S S, Guilleminault C. Emerging drugs for insomnia: new frontiers for old and novel targets. Expert Opin Emerg Drugs: 2009; 14 411 422
34. Nowell P D, Mazumdar S, Buysse D J et al. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA: 1997; 278 2170 2177
35. Pandi-Perumal S R, Srinivasan V, Spence D W et al. Role of the melatonin system in the control of sleep: therapeutic implications. CNS Drugs: 2007; 21 995 1018
36. Mayers A G, Baldwin D S. Antidepressants and their effect on sleep. Hum Psychopharmacol: 2005; 20 533 559
37. Schmid D A, Wichniak A, Uhr M et al. Changes of sleep architecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology: 2006; 31 832 844
38. Croom K F, Perry C M, Plosker G L. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs: 2009; 23 427 452
39. Arnsten A F, Scahill L, Findling R L. alpha2-Adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. J Child Adolesc Psychopharmacol: 2007; 17 393 406
40. Miyazaki S, Uchida S, Mukai J et al. Clonidine effects on all-night human sleep: opposite action of low- and medium-dose clonidine on human NREM-REM sleep proportion. Psychiatry Clin Neurosci: 2004; 58 138 144
41. Philipsen A, Richter H, Schmahl C et al. Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. J Clin Psychiatry: 2004; 65 1414 1419
42. Garrett B N, Kaplan N M. Clonidine in the treatment of hypertension. J Cardiovasc Pharmacol: 1980; 2 01 S61 S71
43. Soyka M, Kranzler H R, van den Brink W et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence. World J Biol Psychiatry: 2011; 12 160 187
44. Onesti G, Bock K D, Heimsoth V et al. Clonidine: a new antihypertensive agent. Am J Cardiol: 1971; 28 74 83
45. Bohrer H, Bach A, Layer M et al. Clonidine as a sedative adjunct in intensive care. Intensive Care Med: 1990; 16 265 266
46. Huang Y S, Tsai M H. Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge. CNS Drugs: 2011; 25 539 554
47. Conner C S, Watanabe A S. Clonidine overdose: a review. Am J Hosp Pharm: 1979; 36 906 911
48. Ernsberger P, Giuliano R, Willette R N et al. Role of imidazole receptors in the vasodepressor response to clonidine analogs in the rostral ventrolateral medulla. J Pharmacol Exp Ther: 1990; 253 408 418
49. th Annual Report. Clin Toxicol (Phila): 2009; 47 911 1084
50. Scahill L. Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness. CNS Drugs: 2009; 23 01 43 49
51. Spiegel R, DeVos J E. Central effects of guanfacine and clonidine during wakefulness and sleep in healthy subjects. Br J Clin Pharmacol: 1980; 10 01 165S 168S
52. Arnsten A F, Cai J X, Goldman-Rakic P S. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes. J Neurosci: 1988; 8 4287 4298
53. Jarrott B, Lewis S J, Doyle A E et al. Effects of continuous infusions (10 days) and cessation of infusions of clonidine and rilmenidine (S 3341) on cardiovascular and behavioral parameters of spontaneously hypertensive rats. Am J Cardiol: 1988; 61 39D 44D
54. Reid J L, Campbell B C, Hamilton C A. Withdrawal reactions following cessation of central alpha-adrenergic receptor agonists. Hypertension: 1984; 6 II71 II75
55. Geyskes G G, Boer P, Dorhout Mees E J. Clonidine withdrawal. Mechanism and frequency of rebound hypertension. Br J Clin Pharmacol: 1979; 7 55 62
56. Pichot C, Ghignone M, Quintin L. Dexmedetomidine and clonidine: from second-to-first-line sedative agents in the critical care setting? J Intensive Care Med: 2011
57. Hoobler S W, Kashima T. Central nervous system actions of clonidine in hypertension. Mayo Clin Proc: 1977; 52 395 398
58. Bonhomme V, Maquet P, Phillips C et al. The effect of clonidine infusion on distribution of regional cerebral blood flow in volunteers. Anesth Analg: 2008; 106 899 909 table of contents
59. Birnbaum S G, Podell D M, Arnsten A F. Noradrenergic alpha-2 receptor agonists reverse working memory deficits induced by the anxiogenic drug, FG7142, in rats. Pharmacol Biochem Behav: 2000; 67 397 403
60. Philipp M, Brede M, Hein L. Physiological significance of alpha(2)-adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol: 2002; 283 R287 R295
61. De Sarro G B, Ascioti C, Froio F et al. Evidence that locus coeruleus is the site where clonidine and drugs acting at alpha 1- and alpha 2-adrenoceptors affect sleep and arousal mechanisms. Br J Pharmacol: 1987; 90 675 685
62. Gentili A, Godschalk M F, Gheorghiu D et al. Effect of clonidine and yohimbine on sleep in healthy men: a double-blind, randomized, controlled trial. Eur J Clin Pharmacol: 1996; 50 463 465
63. Nelson L E, Lu J, Guo T et al. The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. Anesthesiology: 2003; 98 428 436
64. Ebert T J, Hall J E, Barney J A et al. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology: 2000; 93 382 394
65. Venn R M, Bradshaw C J, Spencer R et al. Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit. Anaesthesia: 1999; 54 1136 1142
66. 3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol: 1991; 202 235 243
67. Sorkin E M, Heel R C. Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs: 1986; 31 301 336
68. Kiechel J R. Pharmacokinetics and metabolism of guanfacine in man: a review. Br J Clin Pharmacol: 1980; 10 01 25S 32S
69. Cornish L A. Guanfacine hydrochloride: a centrally acting antihypertensive agent. Clin Pharm: 1988; 7 187 197
70. Kugler J, Seus R, Krauskopf R et al. Differences in psychic performance with guanfacine and clonidine in normotensive subjects. Br J Clin Pharmacol: 1980; 10 01 71S 80S
71. Jakala P, Riekkinen M, Sirvio J et al. Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropsychopharmacology: 1999; 20 460 470
72. Malanga G, Reiter R D, Garay E. Update on tizanidine for muscle spasticity and emerging indications. Expert Opin Pharmacother: 2008; 9 2209 2215
73. Henney H R 3rd, Runyan J D. A clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients. Int J Clin Pract: 2008; 62 314 324
74. Spiller H A, Bosse G M, Adamson L A. Retrospective review of tizanidine (Zanaflex) overdose. J Toxicol Clin Toxicol: 2004; 42 593 596
75. Tanaka H, Fukuda I, Miyamoto A et al. Effects of tizanidine for refractory sleep disturbance in disabled children with spastic quadriplegia. No To Hattatsu: 2004; 36 455 460
76. Peskind E R, Bonner L T, Hoff D J et al. Prazosin reduces trauma-related nightmares in older men with chronic posttraumatic stress disorder. J Geriatr Psychiatry Neurol: 2003; 16 165 171
77. McEvoy G K. ed. drug information 2005. Bethesda, MD American Society of Health-System Pharmacists Inc: 2005; 1742 1746
78. Mallick B N, Alam M N. Different types of norepinephrinergic receptors are involved in preoptic area mediated independent modulation of sleep-wakefulness and body temperature. Brain Res: 1992; 591 8 19
79. Vetrivelan R, Mallick H N, Kumar V M. Tonic activity of alpha1 adrenergic receptors of the medial preoptic area contributes towards increased sleep in rats. Neuroscience: 2006; 139 1141 1151
80. Kumar V M, Vetrivelan R, Mallick H N. Alpha-1 adrenergic receptors in the medial preoptic area are involved in the induction of sleep. Neurochem Res: 2006; 31 1095 1102
81. Pellejero T, Monti J M, Baglietto J et al. Effects of methoxamine and alpha-adrenoceptor antagonists, prazosin and yohimbine, on the sleep-wake cycle of the rat. Sleep: 1984; 7 365 372
82. Larochelle P, du Souich P, Hamet P et al. Prazosin plasma concentration and blood pressure reduction. Hypertension: 1982; 4 93 101
83. Andros E, Detmar-Hanna D, Suteparuk S et al. The effect of aging on the pharmacokinetics and pharmacodynamics of prazosin. Eur J Clin Pharmacol: 1996; 50 41 46
84. Jaillon P. Clinical pharmacokinetics of prazosin. Clin Pharmacokinet: 1980; 5 365 376
85. Lund-Johansen P, Hjermann I, Iversen B M et al. Selective alpha-1 inhibitors: first- or second-line antihypertensive agents? Cardiology: 1993; 83 150 159
86. Melkild A. Prazosin (Peripress): a long-term study. Curr Med Res Opin: 1984; 9 219 228
87. Raskind M A, Peskind E R, Kanter E D et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry: 2003; 160 371 373
88. Raskind M A, Peskind E R, Hoff D J et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry: 2007; 61 928 934
89. McGough J J, Barkley R A. Diagnostic controversies in adult attention deficit hyperactivity disorder. Am J Psychiatry: 2004; 161 1948 1956
90. Philipsen A, Hesslinger B, Tebartz van Elst L. Attention deficit hyperactivity disorder in adulthood: diagnosis, etiology and therapy. Dtsch Arztebl Int: 2008; 105 311 317
91. Polanczyk G, de Lima M S, Horta B L et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry: 2007; 164 942 948
92. Brown R T, Amler R W, Freeman W S et al. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence. Pediatrics: 2005; 115 e749 e757
93. Turner D. A review of the use of modafinil for attention-deficit hyperactivity disorder. Expert Rev Neurother: 2006; 6 455 468
94. Prince J B, Wilens T E, Biederman J et al. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases. J Am Acad Child Adolesc Psychiatry: 1996; 35 599 605
95. Scahill L, Chappell P B, Kim Y S et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry: 2001; 158 1067 1074
96. Spencer T J, Greenbaum M, Ginsberg L D et al. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol: 2009; 19 501 510
97. Sallee F R, Lyne A, Wigal T et al. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol: 2009; 19 215 226
98. Palumbo D R, Sallee F R, Pelham W E Jr et al. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry: 2008; 47 180 188
99. Kessler R C, Berglund P, Demler O et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry: 2005; 62 593 602
100. Ulmer C S, Edinger J D, Calhoun P S. A multi-component cognitive-behavioral intervention for sleep disturbance in veterans with PTSD: a pilot study. J Clin Sleep Med: 2011; 7 57 68
101. Seal K H, Maguen S, Cohen B et al. VA mental health services utilization in Iraq and Afghanistan veterans in the first year of receiving new mental health diagnoses. J Trauma Stress: 2010; 23 5 16
102. Saul A L, Grant K E, Carter J S. Post-traumatic reactions in adolescents: how well do the DSM-IV PTSD criteria fit the real life experience of trauma exposed youth? J Abnorm Child Psychol: 2008; 36 915 925
103. Maher M J, Rego S A, Asnis G M. Sleep disturbances in patients with post-traumatic stress disorder: epidemiology, impact and approaches to management. CNS Drugs: 2006; 20 567 590
104. Mellman T A, Kulick-Bell R, Ashlock L E et al. Sleep events among veterans with combat-related posttraumatic stress disorder. Am J Psychiatry: 1995; 152 110 115
105. Arnsten A F, Mathew R, Ubriani R et al. Alpha-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function. Biol Psychiatry: 1999; 45 26 31
106. Taylor F B, Martin P, Thompson C et al. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry: 2008; 63 629 632
107. Berger W, Mendlowicz M V, Marques-Portella C et al. Pharmacologic alternatives to antidepressants in posttraumatic stress disorder: a systematic review. Prog Neuropsychopharmacol Biol Psychiatry: 2009; 33 169 180
108. Byers M G, Allison K M, Wendel C S et al. Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: an assessment of long-term comparative effectiveness and safety. J Clin Psychopharmacol: 2010; 30 225 229
109. Friedman M J. Toward rational pharmacotherapy for posttraumatic stress disorder: an interim report. Am J Psychiatry: 1988; 145 281 285
110. Boehnlein J K, Kinzie J D. Pharmacologic reduction of CNS noradrenergic activity in PTSD: the case for clonidine and prazosin. J Psychiatr Pract: 2007; 13 72 78
111. Ziegenhorn A A, Roepke S, Schommer N C et al. Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol: 2009; 29 170 173
112. Dahmani S, Brasher C, Stany I et al. Premedication with clonidine is superior to benzodiazepines. A meta analysis of published studies. Acta Anaesthesiol Scand: 2010; 54 397 402
113. Stuhmeier K D, Mainzer B, Cierpka J et al. Small, oral dose of clonidine reduces the incidence of intraoperative myocardial ischemia in patients having vascular surgery. Anesthesiology: 1996; 85 706 712
114. Arain S R, Ebert T J. The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation. Anesth Analg: 2002; 95 461 466 table of contents
115. Szumita P M, Baroletti S A, Anger K E et al. Sedation and analgesia in the intensive care unit: evaluating the role of dexmedetomidine. Am J Health Syst Pharm: 2007; 64 37 44
116. Cohen D J, Young J G, Nathanson J A et al. Clonidine in Tourettes syndrome. Lancet: 1979; 2 551 553
117. Leckman J F, Hardin M T, Riddle M A et al. Clonidine treatment of Gilles de la Tourettes syndrome. Arch Gen Psychiatry: 1991; 48 324 328
118. Goetz C G, Tanner C M, Wilson R S et al. Clonidine and Gilles de la Tourettes syndrome: double-blind study using objective rating methods. Ann Neurol: 1987; 21 307 310
119. Tourettes Syndrome Study Group Treatment of ADHD in children with tics: a randomized controlled trial. Neurology: 2002; 58 527 536
120. Bloch M H, Panza K E, Landeros-Weisenberger A et al. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry: 2009; 48 884 893
121. Trenkwalder C, Paulus W. Restless legs syndrome: pathophysiology, clinical presentation and management. Nat Rev Neurol: 2010; 6 337 346
122. Berger K, Kurth T. RLS epidemiology - frequencies, risk factors and methods in population studies. Mov Disord: 2007; 22 18 S420 S423
123. Trenkwalder C, Benes H, Poewe W et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol: 2008; 7 595 604
124. Wagner M L, Walters A S, Coleman R G et al. Randomized, double-blind, placebo-controlled study of clonidine in restless legs syndrome. Sleep: 1996; 19 52 58
125. Itskovitz H D, Krug K, Khoury S et al. The long-term antihypertensive effects of prazosin and atenolol. Am J Med: 1989; 86 82 86
126. Ferder L, Inserra F, Medina F. Safety aspects of long-term antihypertensive therapy (10 years) with clonidine. J Cardiovasc Pharmacol: 1987; 10 12 S104 S108
127. Khatri I M, Levinson P, Notargiacomo A et al. Initial and long-term effects of prazosin on sympathetic vasopressor responses in essential hypertension. Am J Cardiol: 1985; 55 1015 1018
128. Riemann D, Spiegelhalder K, Feige B et al. The hyperarousal model of insomnia: a review of the concept and its evidence. Sleep Med Rev: 2010; 14 19 31